Unravelling the enhanced vaccine immunity by heterologous KCONVAC/Ad5-nCoV COVID-19 vaccination

Dear Editor,

Growing evidence has indicated that heterologous COVID-19 vaccination could generate higher antibody (Ab) and cell-mediated immune (CMI) responses than homologous vaccination regimen. However, fundamental understanding of immunological mechanisms dictating the enhanced vaccine immunity is still lacking. To gain mechanistic insights, we comprehensively profiled the immune responses generated by homologous or heterologous booster vaccination in mice (Fig. 1a).

C57BL/6 mice were immunized intramuscularly with two doses of inactivated vaccines (KCONVAC, Shenzhen Kangtai) at a 2-week interval, followed by either a homologous booster or a heterologous booster with Ad5-nCoV at week 12. Two doses of KCONVAC induced robust levels of Spike- and RBD-specific IgG, which reached plateau 1 week after 2nd dose (Fig. 1b). While a 3rd dose further stimulated the IgG response irrespective of vaccine type, the heterologous booster induced a significantly higher IgG titer than the homologous control. 7 days after booster, geometric mean titers (GMTs) of anti-Spike IgG in homologous and heterologous vaccination groups were 11,404 and 229,880, respectively. Interestingly, booster with Ad5-nCoV elicited a moderate anti-Spike IgA response (Fig. 1b), which offered additional advantage for heterologous vaccination strategy.

Level of neutralizing Abs against SARS-CoV-2 wide-type strain was dramatically promoted upon heterologous booster and showed a 20-fold increase relative to that induced by homologous booster (Fig. 1c). Importantly, heterologous booster elicited a strikingly higher level of NAbs against the Delta (B.1.617.2) and Omicron (B.1.1.529) variants, albeit at a much lower level than that against the wide-type strain.

Early innate immune activation shapes the adaptive vaccine immunity. We therefore evaluated the innate responses 12 h after booster. Upon heterologous booster, a dramatic upregulation of CD86 on cDC1 from spleen and cDC2 from blood and spleen was observed, which was not seen in homologous booster group (Supplementary Fig. S1). Such response was likely attributed to the self-adjuvant effect of the vehicle since multiple signaling pathways involved in innate activation could be triggered by adenosinergic activation. Whole proteins were employed to profile the global proteome. Principal component analysis of all quantified proteins revealed a distinct distribution among the three groups (Fig. 1d). Differentially expressed protein analysis revealed that heterologous booster significantly altered the plasma protein landscape, with 119 and 31 proteins showing at least 2-fold increased or decreased levels, respectively, when compared to PBS-treated mice. In contrast, levels of plasma proteins in mice receiving homologous booster largely resembled that in PBS-treated mice (Supplementary Fig. S2). Further analysis indicated that proteins with significant changes upon heterologous booster were highly involved in inflammatory responses, antigen uptake/processing and type I interferon response. Many of them showed a clear increase in mice receiving heterologous booster (Fig. 1e). Interestingly, both homologous and heterologous booster induced strong neutrophil activation, indicated by the release of granules such as myeloperoxidase, cathelicidin, neutrophilic granule protein and pentraxin-related protein 3. Splenic neutrophils were also activated, represented by the increased expression of CD40 and CD86 (Supplementary Fig. S3). In addition, booster with Ad5-nCoV increased plasma level of CXCL15, which is chemotactic for neutrophils and highly enriched in pulmonary compartment. Yet, neutrophil activation by COVID-19 vaccination has rarely been reported. Whether the activation of neutrophils is associated with the generation of vaccine responses awaits further investigation.

TH1-type cellular immunity is critical for the control of SARS-CoV-2 infection. Typically, inactivated vaccines adjuvanted with aluminum are more prone to elicit a Th2-type immunity. As was shown in our study, three-dose KCONVAC stimulated a robust level of IL-4-secreting CD4+ T cells (Fig. 1f, g). Only three out of six animals mounted specific CD4+ T cells producing IFN-γ or IL-2. While upon heterologous booster, frequencies of TNF- or IL-2-secreting CD4+ T cells were significantly elevated, and IL-4-secreting T cells were at a comparable level as that induced by homologous booster. A higher proportion of Spike-specific CD4+ T cells produced more than two types of TH1-type cytokines, indicating T cell polyfunctionality (Fig. 1g). IL-21-secreting CD4+ T cells were modestly induced, which suggested generation of TH1 follicular helper cell response. These demonstrated that Ad5-nCoV booster following two-dose KCONVAC elicited a well-balanced TH1/TH2 vaccine response.

The enhanced Ab response by heterologous booster may be attributed to a robust germinal center (GC) reaction. To address this, spleen, lymph node (LN) draining injection site and bone marrow were next analyzed (Fig. 1h, i). Heterologous booster induced a strikingly higher level of class-switched Spike-specific IgG, IgM and IgA PCs in all three lymphoid organs (Fig. 1i). Somatic hypermutation (SHM) is a critical process during GC reaction that determines Ab affinity maturation and clone diversity. To assess this, CD19+ IgD-IgM-Spike+ MBCs from spleen were sorted and subjected to BCR sequencing. Due to limited cell yield, sorted MBCs in each group were pooled together for analysis. Heterologous booster generated more diverse BCR clones, which was likely driven by the higher mutation rates of IGHV and IGHV genes (Fig. 1j). The CDR3 showed higher mutation numbers in both V and J gene segments, accompanied by an increased length (Fig. 1k, l). The pair usage of IGHV-IGHJ genes segments was also assessed. In the homologous booster group, only limited numbers of heavy chain V and J genes were used, with IGHSV1-26-IHGJ3 and IGHSV1-26-IHGJ4 pairs being the most frequently used. In contrast, BCR generated by heterologous booster showed a highly diverse and broad V-J gene usage, as well as much fewer unused pairs, of which IGHSV1-12-IHGJ4, IGHSV2-9-1-IHGJ4, IGHSV9-3-IHGJ1 were the three most abundantly used (Fig. 1m). The top 100

Received: 30 April 2022 Revised: 12 June 2022 Accepted: 22 June 2022
Published online: 04 July 2022

© The Author(s) 2022

www.nature.com/sigtrans

LETTER

Open

Signal Transduction and Targeted Therapy

https://doi.org/10.1038/s41392-022-01079-8
dominant BCR clones in each vaccine group were also identified and a marked increase in BCR clonality was observed in mice receiving heterologous booster (Fig. 1n). The Ig kappa (κ) and lambda (λ) light chains were also sequenced. For Ig λ repertoire, IGLV1-IGLJ1 represented the most frequently used pair accounting for 98.4% and 99.1% of total V-J usages in homologous and heterologous booster group, respectively. While for Ig κ repertoire, heterologous booster generated a much broader V-J gene usage with IGKV6-15-IGKJ1 being the most frequently used. In contrast, the BCR repertoire elicited by homologous booster predominantly used IGKV3-1-IGKJ1.
pair (Supplementary Fig. S4). These data together indicated that heterologous booster with Ad5-nCoV was more efficient at eliciting diverse Spike-specific Ab clones with a higher SHM rate, which was associated with the enhanced anti-viral Ab response.

Clinical evidence has indicated that heterologous COVID-19 vaccine booster was more advantageous than homologous booster, in terms of not only the induction of higher Ab responses but also more efficient protection. Using mouse model, we have comprehensively investigated on many of the aspects involved in the initiation, generation and maintenance of vaccine responses upon homologous or heterologous booster, which provided mechanistic explanations on some of the key questions regarding the enhanced vaccine immunity by heterologous booster. One limitation of our study is that the association between innate activation and generation of high-quality Ab response and GC reaction by heterologous booster was not dissected, which was mainly due to the animal model used and technical limitations. However, manipulating innate compartment via using optimal adjuvants has been widely believed to be a promising strategy that can be deployed for the next-generation COVID-19 vaccine development. A primary two-dose inactivated vaccine followed by adenoviral vectored vaccine booster may therefore hold promise of tackling the challenges posed by continuously emerging SARS-CoV-2 variants and rapidly waning immunity.

DATA AVAILABILITY
All data are available upon reasonable request to the corresponding author.

ACKNOWLEDGEMENTS
The authors thank Shenzhen Kangtai Biological Products Co. Ltd and CanSino Biologics Inc. for kindly providing XCONVAC and Ad5-nCoV vaccines for this study. We also thank the Translational Medicine Core Facility of Shandong University, BioTree and SEQHealth for instrumental and technical support on this study. This project was supported by the Fundamental Research Funds for the Central Universities (26322022Y01, to A.L.), Research Start-up Funds from China Pharmaceutical University (3150120048, to A.L.), Shanghai Pujiang Talent Program (2020PD0068, to A.L.), the National Natural Science Foundation of China (82061138008, to W.T.) and Beijing Municipal Science and Technology Project (Z22110000222017).

AUTHOR CONTRIBUTIONS
A.L., W.T. and X.T. designed the project. W.Z., H.Z., B.H., L.W., X.T., and A.L. performed experiments and analysis; W.Z., H.Z., L.W., J.Z., L.S., Y.Y., X.T., W.T., and A.L. discussed the data; A.L., H.Z. and X.T. wrote the manuscript. All authors have read and approved the manuscript.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41392-022-01079-8.

Competing interests: The authors declare no competing interests.

ETHICS
All animal experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals and the Ethical Committee of Shandong University and using protocols approved by the Institutional Animal Care and Use Committee of Shandong University (approval number: 20023).

REFERENCES
1. Atmar, R. L. et al. Homologous and Heterologous Covid-19 Booster Vaccinations. N. Engl. J. Med. 386, 1046–1057 (2022).
2. Li, J. et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat. Med. 28, 401–409 (2022).
3. WHO. Interim recommendations for heterologous COVID-19 vaccine schedules. World Health Organization. (2021).
4. Sheikh-Mohamed, S. et al. Systemic and mucosal IgG responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal Immunol. (2022).
5. Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728 (2021).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2022